Johnson & Johnson (J&J) has announced that it will present new data from its neuropsychiatry portfolio and pipeline at the upcoming American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami).
The company will highlight its latest research across key neuropsychiatric disorders, including major depressive disorder (MDD), treatment‑resistant depression (TRD) and schizophrenia.
"At Johnson & Johnson, we are focused on addressing the residual symptoms that standard treatments often miss for the millions of patients living with some of today's most prevalent and debilitating neuropsychiatric conditions," said Dr Jane Tiller, Vice President, Global Head of Development, Neuroscience, Innovative Medicine, Johnson & Johnson.
The depth of data being presented across indications at these two meetings underscores our commitment to advancing safe, effective treatment options that may move more patients closer to sustained symptom control, including remission.
At the APA annual meeting, J&J will present long-term data from the CAPLYTA Phase III study evaluating the safety and efficacy of CAPLYTA (lumateperone) for the prevention of relapse in schizophrenia.
Then, at the ASCP annual meeting, the company said it will conduct an oral presentation of data from Phase III efficacy studies on seltorexant as adjunctive therapy in adults with MDD and insomnia symptoms, as well as multiple poster presentations on Phase III studies on CAPLYTA and SPRAVATO.
The company added that it would also participate in a consensus panel at the meeting, focused on long-acting injectables (LAIs) and on recommendations from nurse practitioners (NPs) and physician assistants (PAs) for engaging patients and caregivers in discussions about LAI treatment options for schizophrenia.